Cargando…
1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
Autores principales: | Bayle, A., Baldini, C., Romano, P. Martin, Michot, J-M., Champiat, S., Bahleda, R., Gazzah, A., Marabelle, A., Verlingue, L., Geraud, A., Morel, D., Michiels, S., Ribrag, V., Hollebecque, A., Albiges, L., Besse, B., Soria, J-C., Massard, C., Barlesi, F., Postel-Vinay, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454374/ http://dx.doi.org/10.1016/j.annonc.2021.08.1610 |
Ejemplares similares
-
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic
por: Bayle, Arnaud, et al.
Publicado: (2021) -
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020) -
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
por: Cabel, Luc, et al.
Publicado: (2018) -
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score
por: Pierro, Monica, et al.
Publicado: (2022) -
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
por: Watson, Sarah, et al.
Publicado: (2018)